Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy.
MUC1 is an important target for antibodies in passive cancer immunotherapy. Antibodies against mucin glycans or mucin peptide backbone alone may give rise to cross reactivity with normal tissues. Therefore, attempts to identify antibodies against cancer-specific MUC1 glycopeptide epitopes havebeen made. We recently demonstrated that a monoclonal antibody against the immunodominant Tn-MUC1 (GalNAc-α-MUC1) antigen induced ADCC in breast cancer cell lines, suggesting the feasibility of targeting combined glycopeptide epitopes in future passive cancer immunotherapy.
Department of Cellular and Molecular Medicine, Copenhagen Center for Glycomics and.
Caroline B
CB
Madsen
Hans H
HH
Wandall
Anders Elm
AE
Pedersen
D000818:Animals; D000912:Antibodies, Neoplasm / Q000276:immunology / Q000494:pharmacology*; D000939:Epitopes / Q000276:immunology*; D006801:Humans; D007116:Immunization, Passive; D018396:Mucin-1 / Q000276:immunology*; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology
D000912:Antibodies, Neoplasm; D000939:Epitopes; C060192:MUC1 protein, human; D018396:Mucin-1